The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Dec 2009
Randomized Controlled Trial Multicenter StudyOmalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Many children with asthma continue to experience symptoms despite available therapies. ⋯ Add-on omalizumab is effective and well tolerated as maintenance therapy in children (6 to <12 years) with moderate-to-severe persistent allergic (IgE-mediated) asthma whose symptoms are inadequately controlled despite medium to high doses of ICSs.